海圣医疗（920166）：北交所新股申购策略报告之一百六十：国内麻醉监护耗材头部企业，募投扩产提高市场份额-20260203

Investment Rating - The investment rating for the company is not explicitly stated in the provided documents, but the report suggests active participation in the stock subscription due to its favorable valuation and market position [23]. Core Insights - The company, established in 2000 and headquartered in Shaoxing, Zhejiang, specializes in anesthesia and monitoring medical devices, with a diverse product line that includes anesthesia, monitoring, surgical, and nursing equipment [3][7]. - The company holds a leading market share in the domestic anesthesia and monitoring consumables market, supported by its competitive advantages in core technologies and a strong customer base [3][8]. - Revenue is projected to reach 304 million yuan in 2024, with a three-year CAGR of +6.51%, while net profit is expected to be 70.92 million yuan, with a CAGR of +0.57% [9]. Summary by Sections 1. Company Overview - The company is a leading player in the domestic anesthesia monitoring consumables market, with a strong brand presence and a wide range of products used in various clinical settings [7]. - It has established competitive advantages in key technologies, including invasive blood pressure sensor packaging and bioelectrical signal acquisition [8]. 2. Issuance Plan - The new share issuance will adopt a direct pricing method, with an issue price of 12.64 yuan per share and an initial issuance scale of 11.2941 million shares, accounting for 15% of the total share capital post-issuance [13][14]. - The expected market capitalization after issuance is 952 million yuan, with a PE ratio of 11.09, significantly lower than the median PE of comparable listed companies at 18 [14][26]. 3. Industry Situation - The demand for anesthesia monitoring devices is driven by the aging population and increasing surgical volumes, with over 65 million general anesthesia surgeries performed annually in China [16]. - The global market for medical devices is expanding, and Chinese medical device companies are increasingly gaining a foothold internationally [16]. 4. Competitive Advantages - The company has a comprehensive product matrix that meets the needs of various clinical applications, supported by a robust sales network covering all provinces in China [17]. - It has established long-term partnerships with international medical device companies, enhancing its market position [18]. 5. Comparable Companies - The company’s revenue structure shows a significant focus on anesthesia consumables (52.6%) and monitoring consumables (36.6%), indicating a strong specialization in these areas compared to peers [22].